FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:MARCH9-KCNC2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: MARCH9-KCNC2
FusionPDB ID: 51716
FusionGDB2.0 ID: 51716
HgeneTgene
Gene symbol

MARCH9

KCNC2

Gene ID

92979

3747

Gene namemembrane associated ring-CH-type finger 9potassium voltage-gated channel subfamily C member 2
SynonymsMARCH-IX|MARCH9|RNF179KV3.2
Cytomap

12q14.1

12q21.1

Type of geneprotein-codingprotein-coding
DescriptionE3 ubiquitin-protein ligase MARCH9RING finger protein 179RING-type E3 ubiquitin transferase MARCH9membrane associated ring finger 9membrane-associated RING finger protein 9membrane-associated RING-CH protein IXmembrane-associated ring finger (C3HC4)potassium voltage-gated channel subfamily C member 2potassium channel, voltage gated Shaw related subfamily C, member 2potassium voltage-gated channel, Shaw-related subfamily, member 2shaw-like potassium channelvoltage-gated potassium channel Kv3.2
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000266643, ENST00000548358, 
ENST00000548243, ENST00000298972, 
ENST00000341669, ENST00000350228, 
ENST00000393288, ENST00000540018, 
ENST00000548513, ENST00000549446, 
ENST00000550433, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score9 X 6 X 6=32415 X 5 X 6=450
# samples 1016
** MAII scorelog2(10/324*10)=-1.6959938131099
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(16/450*10)=-1.49185309632967
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: MARCH9 [Title/Abstract] AND KCNC2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: MARCH9 [Title/Abstract] AND KCNC2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)MARCH9(58150867)-KCNC2(75445097), # samples:2
Anticipated loss of major functional domain due to fusion event.MARCH9-KCNC2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MARCH9-KCNC2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MARCH9-KCNC2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MARCH9-KCNC2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:58150867/chr12:75445097)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across MARCH9 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across KCNC2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000266643MARCH9chr1258150867+ENST00000550433KCNC2chr1275445097-3167944142146710
ENST00000266643MARCH9chr1258150867+ENST00000548513KCNC2chr1275445097-3262944142098694
ENST00000266643MARCH9chr1258150867+ENST00000549446KCNC2chr1275445097-5201944142173719
ENST00000266643MARCH9chr1258150867+ENST00000298972KCNC2chr1275445097-3223944142098694
ENST00000266643MARCH9chr1258150867+ENST00000341669KCNC2chr1275445097-3128944142146710
ENST00000266643MARCH9chr1258150867+ENST00000350228KCNC2chr1275445097-3057944141933639
ENST00000266643MARCH9chr1258150867+ENST00000540018KCNC2chr1275445097-2153944142008664
ENST00000266643MARCH9chr1258150867+ENST00000393288KCNC2chr1275445097-2494944142113699

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000266643ENST00000550433MARCH9chr1258150867+KCNC2chr1275445097-0.0047221460.9952779
ENST00000266643ENST00000548513MARCH9chr1258150867+KCNC2chr1275445097-0.0048206020.9951794
ENST00000266643ENST00000549446MARCH9chr1258150867+KCNC2chr1275445097-0.0034841720.99651575
ENST00000266643ENST00000298972MARCH9chr1258150867+KCNC2chr1275445097-0.0052535310.9947464
ENST00000266643ENST00000341669MARCH9chr1258150867+KCNC2chr1275445097-0.0052005950.9947994
ENST00000266643ENST00000350228MARCH9chr1258150867+KCNC2chr1275445097-0.0025867240.99741334
ENST00000266643ENST00000540018MARCH9chr1258150867+KCNC2chr1275445097-0.0261284240.9738715
ENST00000266643ENST00000393288MARCH9chr1258150867+KCNC2chr1275445097-0.012659550.9873404

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MARCH9-KCNC2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
MARCH9chr1258150867KCNC2chr1275445097944307YFKYQVLAISTKNPLQFIAFASLFFI

Top

Potential FusionNeoAntigen Information of MARCH9-KCNC2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MARCH9-KCNC2_58150867_75445097.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:01NPLQFIAF0.97360.81151220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:01ISTKNPLQF0.99890.9775817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B58:02ISTKNPLQF0.99760.9327817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:03ISTKNPLQF0.99650.9748817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:17ISTKNPLQF0.99530.9439817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B58:01ISTKNPLQF0.99430.9101817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:16ISTKNPLQF0.99410.7078817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B39:06TKNPLQFIA0.99210.75951019
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:16STKNPLQFI0.98750.666918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-A30:08STKNPLQFI0.98550.7574918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-A32:13ISTKNPLQF0.6930.9372817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B58:02AISTKNPLQF0.9870.949717
MARCH9-KCNC2chr1258150867chr1275445097944HLA-A30:08STKNPLQFIA0.98660.7702919
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:03AISTKNPLQF0.9840.984717
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:03TKNPLQFIAF0.95910.87531020
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:17LAISTKNPLQF0.99980.9276617
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:03LAISTKNPLQF0.99980.9812617
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:16LAISTKNPLQF0.99950.813617
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B58:01LAISTKNPLQF0.99940.9107617
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:04STKNPLQF0.99890.8814917
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B42:02NPLQFIAF0.93350.64111220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:04STKNPLQFI0.99860.8961918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:06STKNPLQFI0.99790.9362918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:08ISTKNPLQF0.99460.9362817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:19ISTKNPLQF0.98920.9914817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:04ISTKNPLQF0.98580.8952817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:07ISTKNPLQF0.96960.9773817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:06ISTKNPLQF0.95950.937817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B73:01TKNPLQFIA0.95010.55951019
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C04:06ISTKNPLQF0.88180.9257817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C06:03STKNPLQFI0.86240.9892918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C12:04STKNPLQFI0.84890.9932918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:14ISTKNPLQF0.76350.9813817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C12:12STKNPLQFI0.76080.8816918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C12:12ISTKNPLQF0.71540.8928817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C08:13ISTKNPLQF0.58850.9446817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C08:04ISTKNPLQF0.58850.9446817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C02:06STKNPLQFI0.49620.9693918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C12:04ISTKNPLQF0.46880.9922817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C06:03ISTKNPLQF0.4640.9883817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C08:03ISTKNPLQF0.13510.9796817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C02:06ISTKNPLQF0.06040.9461817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:09STKNPLQF0.99890.8814917
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C16:01STKNPLQF0.99490.9821917
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C16:02STKNPLQF0.99040.9935917
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:77NPLQFIAF0.97360.81151220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:23NPLQFIAF0.97290.79421220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:11NPLQFIAF0.9720.82911220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:17NPLQFIAF0.96870.65731220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:30NPLQFIAF0.96870.65731220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B35:24NPLQFIAF0.95210.76351220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B18:07NPLQFIAF0.81680.761220
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:10ISTKNPLQF0.99890.9775817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:02STKNPLQFI0.99870.8924918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:09STKNPLQFI0.99860.8961918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:05STKNPLQFI0.99830.9043918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B58:06ISTKNPLQF0.99750.7567817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:02ISTKNPLQF0.99750.9789817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:04ISTKNPLQF0.99740.6125817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:04ISTKNPLQF0.99560.992817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:03ISTKNPLQF0.99560.992817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:02ISTKNPLQF0.9890.7839817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-A30:01STKNPLQFI0.98720.8413918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:09ISTKNPLQF0.98580.8952817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:17ISTKNPLQF0.97660.9797817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:05ISTKNPLQF0.97380.9622817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C06:06ISTKNPLQF0.95560.9868817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C16:04ISTKNPLQF0.94150.9698817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C16:02STKNPLQFI0.92020.993918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:24ISTKNPLQF0.91680.9546817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:05ISTKNPLQF0.89960.9393817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C15:02ISTKNPLQF0.8740.9209817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-A69:01STKNPLQFI0.82330.8748918
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C12:02ISTKNPLQF0.76710.9656817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C12:03ISTKNPLQF0.7560.9704817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C16:01ISTKNPLQF0.69420.9828817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C03:06ISTKNPLQF0.62640.9912817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C16:02ISTKNPLQF0.56620.9906817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C08:01ISTKNPLQF0.13510.9796817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C02:02ISTKNPLQF0.13050.9588817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-C02:10ISTKNPLQF0.13050.9588817
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:02AISTKNPLQF0.99070.9468717
MARCH9-KCNC2chr1258150867chr1275445097944HLA-A30:01STKNPLQFIA0.98580.8675919
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:68TKNPLQFIAF0.96620.69171020
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B15:54TKNPLQFIAF0.95660.92891020
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B48:02TKNPLQFIAF0.91390.95031020
MARCH9-KCNC2chr1258150867chr1275445097944HLA-B57:02LAISTKNPLQF0.99970.9421617

Top

Potential FusionNeoAntigen Information of MARCH9-KCNC2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MARCH9-KCNC2_58150867_75445097.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1117KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1117YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1117FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1117QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1152KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1152YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1152FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1152QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1189KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1189YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1189FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1331YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1331KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1377KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1377YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1401KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1401FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1401YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1401QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1404KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1404FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1404YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1404QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1405KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1405YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1405FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1405QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1407KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1407YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1407FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1407QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1408KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1408YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1408FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1408QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1411KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1411YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1411FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1411QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1414KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1414YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1414FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1418KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1418YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1418FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1418QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1423KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1423YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1423FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1423QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1426KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1426FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1426YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1426QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1428KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1428YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1428FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1428QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1431KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1431YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1431FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1432KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1432YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1432FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1432QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1433KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1434KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1434YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1434FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1435KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1435YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1435FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1435QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1436KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1436YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1436FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1438KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1438YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1438FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1438QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1439KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1439YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1439FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1439QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1442KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1442YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1442FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1443KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1443YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1443FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1443QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1444KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1444YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1444FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1445KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1445YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1445FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1445QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1449KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1449YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1450KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1450YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1450FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1450QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1454KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1454FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1454YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1454QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1455YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1455KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1455FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1455QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1456KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1456YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1456FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1456QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1458KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1458FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1458YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1458QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1459KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1459YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1459FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1459QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1460KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1460FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1460YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1460QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1461KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1461FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1461YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1461QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1462KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1462FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1462YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1462QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1462YFKYQVLAISTKNPL015
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1464KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1464YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1464FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1464QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1465KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1465YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1465FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1468KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1468YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1468FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1468QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1470KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1470YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1470FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1470QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1471KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1471YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1471FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1471QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1472KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1472YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1472FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1472QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1473KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1474KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1475KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1475FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1475YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1475QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1481YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1481KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1482KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1482FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1482YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1482QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1482YFKYQVLAISTKNPL015
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1486KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1486FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1486YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1486QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1487KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1487FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1487YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1487QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1488KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1488FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1488YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1488QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1490KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1490FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1490YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1490QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1491KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1491YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1491FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1491QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1493KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1493YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1493FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1493QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1495KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1495YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1495FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1495QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1496KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1496YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1496FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1496QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1497KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1497FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1497YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1497QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1499KYQVLAISTKNPLQF217
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1499YQVLAISTKNPLQFI318
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1499FKYQVLAISTKNPLQ116
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1499QVLAISTKNPLQFIA419
MARCH9-KCNC2chr1258150867chr1275445097944DRB1-1499YFKYQVLAISTKNPL015

Top

Fusion breakpoint peptide structures of MARCH9-KCNC2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4749LAISTKNPLQFIAFMARCH9KCNC2chr1258150867chr1275445097944

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MARCH9-KCNC2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B53:011A1O4749LAISTKNPLQFIAF-4.17128-4.28468
HLA-B53:011A1O4749LAISTKNPLQFIAF-3.4824-4.5177
HLA-B51:011E284749LAISTKNPLQFIAF-3.8039-3.9173
HLA-B51:011E284749LAISTKNPLQFIAF-3.0982-4.1335
HLA-B57:032BVO4749LAISTKNPLQFIAF-2.25252-3.28782
HLA-B57:032BVO4749LAISTKNPLQFIAF-1.1301-1.2435
HLA-A03:012XPG4749LAISTKNPLQFIAF-4.44786-4.56126
HLA-A03:012XPG4749LAISTKNPLQFIAF-4.14835-5.18365
HLA-B14:023BVN4749LAISTKNPLQFIAF-5.80238-5.91578
HLA-B14:023BVN4749LAISTKNPLQFIAF-3.55223-4.58753
HLA-B52:013W394749LAISTKNPLQFIAF-5.11856-5.23196
HLA-B52:013W394749LAISTKNPLQFIAF-3.25922-4.29452
HLA-B18:014JQV4749LAISTKNPLQFIAF-4.41315-4.52655
HLA-B18:014JQV4749LAISTKNPLQFIAF-3.36095-4.39625
HLA-A11:014UQ24749LAISTKNPLQFIAF-8.56989-8.68329
HLA-A11:014UQ24749LAISTKNPLQFIAF-6.72556-7.76086
HLA-A24:025HGA4749LAISTKNPLQFIAF-6.2734-6.3868
HLA-A24:025HGA4749LAISTKNPLQFIAF-4.24193-5.27723
HLA-B57:015VUD4749LAISTKNPLQFIAF-3.95679-4.99209
HLA-B57:015VUD4749LAISTKNPLQFIAF-2.97944-3.09284
HLA-C08:026JTP4749LAISTKNPLQFIAF-4.74128-4.85468
HLA-C08:026JTP4749LAISTKNPLQFIAF-2.44773-3.48303
HLA-B37:016MT44749LAISTKNPLQFIAF-3.77829-4.81359
HLA-B27:056PYJ4749LAISTKNPLQFIAF-3.40019-3.51359
HLA-B27:056PYJ4749LAISTKNPLQFIAF-1.99024-3.02554
HLA-B27:036PZ54749LAISTKNPLQFIAF-3.1249-3.2383
HLA-B27:036PZ54749LAISTKNPLQFIAF-0.148491-1.18379
HLA-B44:053DX84749LAISTKNPLQFIAF-5.76333-5.87673
HLA-B44:053DX84749LAISTKNPLQFIAF-3.98513-5.02043
HLA-B44:021M6O4749LAISTKNPLQFIAF-1.76802-2.80332
HLA-B07:025EO04749LAISTKNPLQFIAF-3.47003-3.58343
HLA-B07:025EO04749LAISTKNPLQFIAF0.983323-0.0519774
HLA-A02:016TDR4749LAISTKNPLQFIAF-2.71064-3.74594
HLA-A02:016TDR4749LAISTKNPLQFIAF-2.80613-2.91953

Top

Vaccine Design for the FusionNeoAntigens of MARCH9-KCNC2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
MARCH9-KCNC2chr1258150867chr12754450971019TKNPLQFIACCACTGCAGTTTATTGCTTTTGCTTCT
MARCH9-KCNC2chr1258150867chr12754450971020TKNPLQFIAFCCACTGCAGTTTATTGCTTTTGCTTCTTTA
MARCH9-KCNC2chr1258150867chr12754450971220NPLQFIAFCAGTTTATTGCTTTTGCTTCTTTA
MARCH9-KCNC2chr1258150867chr1275445097617LAISTKNPLQFAGCACCAAGAACCCACTGCAGTTTATTGCTTTT
MARCH9-KCNC2chr1258150867chr1275445097717AISTKNPLQFACCAAGAACCCACTGCAGTTTATTGCTTTT
MARCH9-KCNC2chr1258150867chr1275445097817ISTKNPLQFAAGAACCCACTGCAGTTTATTGCTTTT
MARCH9-KCNC2chr1258150867chr1275445097917STKNPLQFAACCCACTGCAGTTTATTGCTTTT
MARCH9-KCNC2chr1258150867chr1275445097918STKNPLQFIAACCCACTGCAGTTTATTGCTTTTGCT
MARCH9-KCNC2chr1258150867chr1275445097919STKNPLQFIAAACCCACTGCAGTTTATTGCTTTTGCTTCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
MARCH9-KCNC2chr1258150867chr1275445097015YFKYQVLAISTKNPLTACCAGGTCCTGGCGATCAGCACCAAGAACCCACTGCAGTTTATT
MARCH9-KCNC2chr1258150867chr1275445097116FKYQVLAISTKNPLQCAGGTCCTGGCGATCAGCACCAAGAACCCACTGCAGTTTATTGCT
MARCH9-KCNC2chr1258150867chr1275445097217KYQVLAISTKNPLQFGTCCTGGCGATCAGCACCAAGAACCCACTGCAGTTTATTGCTTTT
MARCH9-KCNC2chr1258150867chr1275445097318YQVLAISTKNPLQFICTGGCGATCAGCACCAAGAACCCACTGCAGTTTATTGCTTTTGCT
MARCH9-KCNC2chr1258150867chr1275445097419QVLAISTKNPLQFIAGCGATCAGCACCAAGAACCCACTGCAGTTTATTGCTTTTGCTTCT

Top

Information of the samples that have these potential fusion neoantigens of MARCH9-KCNC2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BLCAMARCH9-KCNC2chr1258150867ENST00000266643chr1275445097ENST00000298972TCGA-BT-A20X-01A

Top

Potential target of CAR-T therapy development for MARCH9-KCNC2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneKCNC2chr12:58150867chr12:75445097ENST0000029897216230_2500599.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000029897216284_3030599.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000029897216314_3340599.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000029897216346_3680599.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000029897216382_4020599.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000029897216453_4730599.0TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000034166915230_2500630.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000034166915284_3030630.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000034166915314_3340630.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000034166915346_3680630.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000034166915382_4020630.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000034166915453_4730630.0TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000035022815230_2500543.6666666666666TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000035022815284_3030543.6666666666666TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000035022815314_3340543.6666666666666TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000035022815346_3680543.6666666666666TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000035022815382_4020543.6666666666666TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000035022815453_4730543.6666666666666TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000039328815230_2500619.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000039328815284_3030619.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000039328815314_3340619.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000039328815346_3680619.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000039328815382_4020619.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000039328815453_4730619.0TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054001814230_2500584.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054001814284_3030584.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054001814314_3340584.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054001814346_3680584.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054001814382_4020584.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054001814453_4730584.0TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054851305230_2500477.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054851305284_3030477.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054851305314_3340477.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054851305346_3680477.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054851305382_4020477.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054851305453_4730477.0TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054944615230_2500639.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054944615284_3030639.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054944615314_3340639.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054944615346_3680639.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054944615382_4020639.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000054944615453_4730639.0TransmembraneHelical%3B Name%3DSegment S6
TgeneKCNC2chr12:58150867chr12:75445097ENST0000055043304230_2500630.0TransmembraneHelical%3B Name%3DSegment S1
TgeneKCNC2chr12:58150867chr12:75445097ENST0000055043304284_3030630.0TransmembraneHelical%3B Name%3DSegment S2
TgeneKCNC2chr12:58150867chr12:75445097ENST0000055043304314_3340630.0TransmembraneHelical%3B Name%3DSegment S3
TgeneKCNC2chr12:58150867chr12:75445097ENST0000055043304346_3680630.0TransmembraneHelical%3B Voltage-sensor%3B Name%3DSegment S4
TgeneKCNC2chr12:58150867chr12:75445097ENST0000055043304382_4020630.0TransmembraneHelical%3B Name%3DSegment S5
TgeneKCNC2chr12:58150867chr12:75445097ENST0000055043304453_4730630.0TransmembraneHelical%3B Name%3DSegment S6

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to MARCH9-KCNC2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to MARCH9-KCNC2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource